Syncromune, Inc. develops SYNC-T™, a personalized intratumoral immunotherapy that combines partial oncolysis with the infusion of a multi-target biologic drug directly into solid tumors. This approach activates patient-specific T cells to enhance systemic anti-tumor responses, addressing the immune suppression commonly seen in metastatic solid tumor cancers.
Funding
$130.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic solid tumors often exhibit immune suppression, hindering effective anti-tumor immune responses. Current systemic immunotherapies may not adequately address the complex immune evasion mechanisms within the tumor microenvironment.
Solution
Syncromune develops SYNC-T™, a personalized intratumoral immunotherapy designed to overcome immune suppression in solid tumors. The SYNC-T platform combines partial oncolysis with the direct infusion of a multi-target biologic drug into the tumor. This in situ approach aims to simultaneously address multiple immune suppression mechanisms while stimulating the immune system. The therapy is designed to activate and proliferate patient-specific T cells, enabling them to migrate and attack tumors systemically throughout the body.
Target Audience
The primary target audience includes healthcare professionals treating patients with advanced metastatic solid tumor cancers.
Features
- Personalized intratumoral delivery of a multi-target biologic drug.
- Combination of partial oncolysis and immunostimulation within the tumor microenvironment.
- Designed to activate and expand patient-specific T cells for systemic anti-tumor activity.